Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01046825 · ClinicalTrials.gov registry record · Phase 2

Mature B-Cell Lymphoma And Leukemia Study III

A Phase 2 study of Mature B-Cell Lymphoma, sponsored by St. Jude Children's Research Hospital.

Active
Registry status
Phase 2
Development phase
128
Enrollment target
4
Study locations

NCT01046825 is a Phase 2 study of Mature B-Cell Lymphoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 128 participants. The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01046825, a Phase 2 study of Mature B-Cell Lymphoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
128 participants
Enrollment target
4
Study locations

Study Summary

This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for children with B-cell NHL are excellent. Further improvements in outcome will likely be achieved through more focused study of the biology of the tumors and prospective studies of the late effects of treatment. Toward this end, this study features a spectrum of prospective biologic and late effect studies performed in patients treated with a modified regimen derived from the very successful LMB-96 regimen.

Conditions Studied

Interventions

  • DRUG COPAD
  • DRUG COP, COPD M3, CYM
  • DRUG COP, COPADM8, CYVE

Study Locations (4)

Other

  • Children's Cancer Hospital - Cairo
  • National University Health System - Singapore

California

  • Rady Children's Hospital San Diego - San Diego

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2010-09-09
Est. Completion 2027-08
Phase Phase 2

What the Registry Record Tells You About NCT01046825

The ClinicalTrials.gov registry entry for NCT01046825 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mature B-Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which COPAD is the first listed.

NCT01046825 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT01046825 about?

NCT01046825 is a clinical study titled "Mature B-Cell Lymphoma And Leukemia Study III". This is a phase III clinical trial using risk-adapted therapy. Treatment outcomes for children with B-cell NHL are excellent. Further improvements in outcome will likely be achieved through more focused study of the biology of the tumors and prospective studies of the late effects of treatment. Towa...

What is the current status of trial NCT01046825?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2010-09-09. Estimated completion is 2027-08.

What conditions does trial NCT01046825 study?

This clinical trial studies the following conditions: Mature B-Cell Lymphoma.

What interventions are being tested in trial NCT01046825?

The interventions under investigation include: COPAD (DRUG), COP, COPD M3, CYM (DRUG), COP, COPADM8, CYVE (DRUG).

Who is sponsoring clinical trial NCT01046825?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01046825 being conducted?

This trial has 4 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.